Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ellis

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
Bioorganic & Medicinal Chemistry|November 22, 2011
The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokineticsDavid J Rawson, Stephen Ballard, Christopher Barber, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2009
The design and discovery of novel amide CCR5 antagonistsDavid C Pryde, Martin Corless, David R Fenwick, et al.
Journal of Medicinal Chemistry|December 7, 2010
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)Paul A Stupple, David V Batchelor, Martin Corless, et al.
Pediatric Neurology|February 15, 2023
The Spectrum of MORC2-Related Disorders: A Potential Link to Cockayne SyndromeSeth A Stafki, Johnnie Turner, Hannah R Littel, et al.
Diagnostic Microbiology and Infectious Disease|March 27, 2010
Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance ProgramMichael A Pfaller, Daniel J Diekema, David L Gibbs, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymeraseSun Hee Kim, Martin T Tran, Frank Ruebsam, et al.
Journal of Clinical Microbiology|August 7, 2004
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus speciesFrank C Odds, Mary Motyl, Roberto Andrade, et al.
Journal of Medicinal Chemistry|July 7, 2017
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na<sub>V</sub>1.7Nigel A Swain, Dave Batchelor, Serge Beaudoin, et al.
Msphere|January 20, 2017
The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of CryptococcosisKyung J Kwon-Chung, John E Bennett, Brian L Wickes, et al.
Nature Plants|May 9, 2022
State of ex situ conservation of landrace groups of 25 major cropsJulian Ramirez-Villegas, Colin K Khoury, Harold A Achicanoy, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
Bioorganic & Medicinal Chemistry|November 22, 2011
The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokineticsDavid J Rawson, Stephen Ballard, Christopher Barber, et al.
Bioorganic & Medicinal Chemistry Letters|January 27, 2009
The design and discovery of novel amide CCR5 antagonistsDavid C Pryde, Martin Corless, David R Fenwick, et al.
Journal of Medicinal Chemistry|December 7, 2010
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)Paul A Stupple, David V Batchelor, Martin Corless, et al.
Pediatric Neurology|February 15, 2023
The Spectrum of MORC2-Related Disorders: A Potential Link to Cockayne SyndromeSeth A Stafki, Johnnie Turner, Hannah R Littel, et al.
Diagnostic Microbiology and Infectious Disease|March 27, 2010
Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance ProgramMichael A Pfaller, Daniel J Diekema, David L Gibbs, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymeraseSun Hee Kim, Martin T Tran, Frank Ruebsam, et al.
Journal of Clinical Microbiology|August 7, 2004
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus speciesFrank C Odds, Mary Motyl, Roberto Andrade, et al.
Journal of Medicinal Chemistry|July 7, 2017
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na<sub>V</sub>1.7Nigel A Swain, Dave Batchelor, Serge Beaudoin, et al.
Msphere|January 20, 2017
The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of CryptococcosisKyung J Kwon-Chung, John E Bennett, Brian L Wickes, et al.
Nature Plants|May 9, 2022
State of ex situ conservation of landrace groups of 25 major cropsJulian Ramirez-Villegas, Colin K Khoury, Harold A Achicanoy, et al.
Pageof 18